Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1054 participants.
Also called NCT01001962
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 1,054 participants
- Registry
-
NCT01001962
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Greece
- Registry status
- Unknown status
Technical summary
Registry record NCT01001962. Randomized; triple masking; primary purpose prevention. Start 2016-01 (registry gives no type); primary completion 2019-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
- Acronym
- PREHYPD
- Condition
- Hypertension
- Condition
- Type II Diabetes
- Intervention (Drug)
- empagliflozin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Aristotle University Of Thessaloniki
Record details
- Record id
cardio:ct-nct01001962- Content hash
7de8025840aeabaf0206c88cdf9715969c0885ee256a04e2b4d53ef2fd80d7ce